
  
    
      
        Introduction_NNP
        Synovial_NNP tissues_NNS isolated_VBN from_IN patients_NNS with_IN rheumatoid_NN
        arthritis_NN (_( RA_NNP )_) display_NN biologic_JJ properties_NNS that_WDT differ_VBP from_IN
        '_POS normal_JJ '_POS synovium_NN ,_, and_CC there_EX is_VBZ a_DT rapidly_RB expanding_VBG
        catalogue_NN of_IN biochemical_JJ and_CC molecular_JJ changes_NNS that_WDT
        underlie_VB this_DT phenotype_NN [_NN 1_CD ]_NN ._. We_PRP have_VBP investigated_VBN the_DT
        feasibility_NN of_IN using_VBG Moloney_NNP murine_NN leukemia_NN virus_NN (_( MoMLV_NNP )_)
        based_VBN vectors_NNS to_TO constitutively_RB express_VB cloned_VBN genes_NNS in_IN
        primary_JJ human_JJ fibroblast-like_JJ synovial_NN cells_NNS (_( FLS_NNP )_) ,_, with_IN
        the_DT long-term_JJ objective_NN of_IN defining_VBG the_DT contributions_NNS of_IN
        specific_JJ signaling_VBG pathways_NNS and_CC inflammatory_JJ mediators_NNS to_TO
        the_DT destructive_JJ phenotype_NN of_IN FLS_NNP in_IN RA_NNP ._.
        Prior_RB studies_VBZ have_VBP suggested_VBN that_IN MoMLV-based_NNP vectors_NNS
        transduced_JJ FLS_NNP with_IN relatively_RB low_JJ efficiency_NN [_NN 2_CD 3_CD 4_CD 5_CD ]_NN ._.
        We_PRP designed_VBD experiments_NNS to_TO determine_VB if_IN viral_JJ titer_NN
        influenced_VBD FLS_NNP transduction_NN by_IN concentration_NN of_IN retrovirus_JJ ._.
        In_IN these_DT experiments_NNS ,_, we_PRP used_VBD a_DT modified_VBN MoMLV_NNP vector_NN
        (_( pRET_NN 2_LS )_) ,_, designed_VBN to_TO improve_VB transcriptional_NN stability_NN in_IN
        primary_JJ cells_NNS ._. We_PRP also_RB employed_VBN the_DT enhanced_VBN green_JJ
        fluorescent_NN protein_NN (_( EGFP_NNP )_) as_IN a_DT virally_RB encoded_JJ transgene_NN
        to_TO optimize_NN a_DT rapid_JJ and_CC efficient_JJ superspeed_JJ centrifugation_NN
        technique_NN for_IN concentration_NN of_IN viral_JJ supernatant_NN ._. Viral_NNP
        particles_NNS were_VBD concentrated_VBN to_TO >_NN 10_CD 8_CD colony_NN forming_VBG units_NNS
        (_( cfu_NN )_) /_NN ml_NN by_IN superspeed_JJ centrifugation_NN at_IN 20_CD ,_, 000_CD 
        g_SYM for_IN four_CD hours_NNS ._. Up_IN to_TO 50_CD %_NN of_IN
        primary_JJ human_JJ FLS_NNP were_VBD transduced_JJ 
        in_IN vitro_NN following_VBG a_DT single_JJ exposure_NN
        to_TO concentrated_VBN viral_JJ supernatant_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Cell_NNP Culture_NNP
          Murine_NNP fibroblast_NN NIH_NNP 3_CD T_NN 3_CD cells_NNS ,_, amphotropic_JJ PA_NNP 317_CD
          packaging_NN cells_NNS ,_, and_CC Phoenix_NNP E_NNP ecotropic_JJ packaging_NN cells_NNS
          were_VBD cultured_JJ in_IN Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS medium_NN
          (_( DMEM_NNP )_) -_: high_JJ glucose_NN (_( GIBCO-BRL_NNP ,_, Grand_NNP island_NN ,_, NY_NNP ,_, USA_NNP )_)
          supplemented_JJ with_IN 10_CD %_NN heat-inactivated_JJ fetal_JJ bovine_JJ serum_NN
          (_( GIBCO-BRL_NNP ,_, Grand_NNP island_NN ,_, NY_NNP ,_, USA_NNP )_) ,_, 100_CD U_NNP /_NN ml_NN penicillin_NN ,_,
          100_CD μg_NN /_NN ml_NN streptomycin_NN ,_, and_CC 200_CD mM_NN L-_NNP glutamine_NN ._. The_DT FLS_NNP
          cultures_NNS were_VBD established_VBN from_IN synovial_NN tissues_NNS obtained_VBN
          during_IN joint_JJ replacement_NN surgery_NN in_IN RA_NNP patients_NNS [_NN 6_CD ]_NN ._.
          The_DT FLS_NNP were_VBD cultured_JJ in_IN DMEM_NNP plus_CC 10_CD %_NN heat-inactivated_JJ
          human_JJ AB_NNP serum_NN (_( BioWhittaker_NNP ,_, Walkersville_NNP ,_, MD_NNP ,_, USA_NNP )_) ,_, 10_CD %_NN
          fetal_JJ bovine_JJ serum_NN ,_, penicillin_NN ,_, streptomycin_NN ,_, and_CC
          L-_NNP glutamine_NN ._. The_DT FLS_NNP were_VBD used_VBN between_IN the_DT third_NN and_CC
          tenth_NN passage_NN ._.
        
        
          Construction_NNP of_IN retroviral_NN vector_NN and_CC producer_NN
          cells_NNS
          The_DT EGFP_NNP cDNA_NN was_VBD PCR_NNP amplified_VBN from_IN pEGFP-_NN 1_CD
          (_( Clontech_NNP ,_, Palo_NNP Alto_NNP ,_, CA_NNP ,_, USA_NNP )_) and_CC subcloned_JJ into_IN pRET_NN 2_CD ,_,
          a_DT modified_VBN version_NN of_IN the_DT MoMLV-based_NNP MFG_NNP retroviral_NN
          vector_NN ,_, designed_VBN to_TO optimize_NN gene_NN expression_NN in_IN primary_JJ
          cell_NN lines_NNS ._. The_DT pRET_NN 2_CD incorporates_VBZ long-terminal_JJ repeats_NNS
          from_IN the_DT myeloproliferative_JJ sarcoma_NN virus_NN [_NN 7_CD ]_NN ,_, and_CC a_DT
          point_NN mutation_NN in_IN the_DT primer_NN binding_JJ site_NN [_NN 8_CD ]_NN ._. A_DT
          vector_NN expressing_VBG the_DT human_JJ cyclooxygenase-_NN 2_CD (_( COX-_NNP 2_LS )_) cDNA_NN
          was_VBD constructed_VBN in_IN the_DT same_JJ backbone_NN (_( pRET_NN 2_CD ._. COX_NNP 2_LS )_) ._.
          Amphotropic_NNP viral_JJ producers_NNS were_VBD established_VBN in_IN PA_NNP 317_CD
          cells_NNS (_( see_VB Supplementary_NNP Material_NNP )_) ._.
        
        
          Concentration_NNP of_IN viral_JJ supernatant_NN by_IN superspeed_JJ
          centrifugation_NN
          Fresh_NNP medium_NN was_VBD added_VBN to_TO subconfluent_NN producer_NN cell_NN
          monolayers_NNS ,_, collected_VBD 24_CD hours_NNS later_RB ,_, and_CC filtered_VBN (_( 0_CD ._. 45_CD
          μM_NN )_) prior_RB to_TO use_VB ._. Centrifugation_NNP was_VBD performed_VBN at_IN 4_CD °_NN C_NNP in_IN
          a_DT Sorval_NNP RC-_NNP 5_CD B_NNP centrifuge_NN ,_, using_VBG SS-_NNP 34_CD or_CC GSA_NNP rotors_NNS ._.
          Following_VBG centrifugation_NN ,_, the_DT supernatant_NN was_VBD aspirated_JJ
          and_CC saved_VBN for_IN analysis_NN ._. The_DT viral_JJ pellet_NN was_VBD resuspended_JJ
          in_IN fresh_JJ medium_NN by_IN gentle_JJ pipetting_VBG ._.
        
        
          Quantitation_NNP of_IN viral_JJ RNA_NNP by_IN slot_NN blot_NN
          hybridization_NN
          Viral_NNP RNA_NNP was_VBD quantitated_JJ using_VBG a_DT slot_NN blot_NN
          hybridization_NN technique_NN ._. See_VB Supplementary_NNP Material_NNP for_IN
          full_JJ details_NNS ._.
        
        
          Quantitation_NNP of_IN retroviral_NN titer_NN by_IN flow_NN cytometry_NN
          based_VBD expression_NN analysis_NN for_IN EGFP_NNP
          We_PRP developed_VBD a_DT flow_NN cytometry_NN assay_NN to_TO rapidly_RB measure_VB
          the_DT titer_NN of_IN infectious_JJ viral_JJ particles_NNS (_( Fig_NNP ._. 1_LS )_) ._. This_DT
          assay_NN takes_VBZ advantage_NN of_IN the_DT fluorescent_NN properties_NNS of_IN
          the_DT EGFP_NNP transgene_NN ._. A_DT total_NN of_IN 2_CD ×_NN 10_CD 5_CD NIH_NNP 3_CD T_NN 3_CD cells_NNS were_VBD
          transduced_JJ with_IN serial_NN dilutions_NNS of_IN supernatant_NN ._. The_DT
          transduction_NN efficiency_NN was_VBD measured_VBN by_IN flow_NN cytometry_NN ,_,
          and_CC viral_JJ titer_NN was_VBD calculated_VBN at_IN limiting_VBG dilution_NN
          according_VBG to_TO the_DT following_JJ formula_NN :_:
          Titer_NNP (_( cfu_NN /_NN ml_NN )_) =_SYM (_( 2_CD ×_NN 10_CD 5_CD target_NN cells_NNS )_) ×_NN (_( %_NN EGFP_NNP +_NN
          cells_NNS )_) /_NN volume_NN of_IN supernatant_NN (_( ml_NN )_) ._.
          See_VB Supplementary_NNP Material_NNP for_IN full_JJ details_NNS ._.
        
        
          Transduction_NNP of_IN primary_JJ human_JJ FLS_NNP
          The_DT FLS_NNP were_VBD plated_JJ in_IN 6_CD -_: well_RB dishes_NNS at_IN 2_CD ×_NN 10_CD
          5_CD cells_NNS /_NN well_RB ._. FLS_NNP were_VBD cultured_JJ with_IN viral_JJ supernatant_NN
          plus_CC protamine_NN sulfate_NN (_( 5_CD μg_NN /_NN ml_NN )_) for_IN 24_CD hours_NNS ._. Cells_NNP were_VBD
          analyzed_VBN for_IN transgene_NN expression_NN 72_CD hours_NNS after_IN
          infection_NN ._.
        
      
      
        Results_NNS
        
          Concentration_NNP of_IN viral_JJ supernatant_NN
          To_TO determine_VB if_IN viral_JJ titer_NN influenced_VBD the_DT
          transduction_NN efficiency_NN of_IN FLS_NNP ,_, we_PRP optimized_JJ a_DT superspeed_JJ
          centrifugation_NN protocol_NN for_IN concentration_NN of_IN viral_JJ
          supernatant_NN ._. Prior_RB studies_VBZ reported_VBD improved_VBN transduction_NN
          of_IN primary_JJ cells_NNS with_IN retro-virus_JJ concentrated_VBN by_IN
          centrifugation_NN at_IN 6000_CD 
          g_SYM for_IN 16_CD hours_NNS [_NN 9_CD 10_CD 11_CD ]_NN ._. We_PRP
          systematically_RB evaluated_VBD different_JJ centrifugation_NN
          parameters_NNS to_TO minimize_VB the_DT time_NN required_VBN for_IN maximal_NN
          concentration_NN while_IN preserving_VBG viral_JJ infectivity_NN ._. A_DT
          virally_RB encoded_JJ EGFP_NNP transgene_NN [_NN 12_CD 13_CD 14_CD ]_NN was_VBD used_VBN to_TO
          monitor_VB viral_JJ concentration_NN and_CC infectious_JJ titer_NN ._. We_PRP
          concentrated_VBD viral_JJ supernatant_NN 100_CD -_: fold_VB in_IN as_RB few_JJ as_IN four_CD
          hours_NNS by_IN centrifugation_NN at_IN 20_CD ,_, 000_CD 
          g_SYM ,_, with_IN complete_JJ recovery_NN of_IN
          infectious_JJ viral_JJ particles_NNS ._. This_DT data_NNS is_VBZ presented_VBN in_IN the_DT
          Supplementary_NNP Material_NNP (_( Supplementary_NNP Figs_NNP s_VBZ 1_CD ,_, s_VBZ 2_CD ,_, s_VBZ 3_CD ,_,
          and_CC s_VBZ 4_LS )_) ._.
        
        
          Retroviral_NNP transduction_NN of_IN primary_JJ human_JJ
          synoviocytes_NNS
          Concentrated_NNP virus_NN was_VBD tested_VBN for_IN its_PRP$ ability_NN to_TO
          transduce_NN primary_JJ FLS_NNP ._. As_IN shown_VBN in_IN Figure_NN 2_CD and_CC Table_NNP 1_CD ,_,
          concentration_NN of_IN viral_JJ supernatant_NN increased_VBD FLS_NNP
          transduction_NN ._. We_PRP found_VBD that_DT 14_CD ._. 2_LS ±_NN 8_CD ._. 2_CD %_NN of_IN FLS_NNP expressed_VBD
          EGFP_NNP following_VBG transduction_NN with_IN unconcentrated_JJ
          supernatant_NN ,_, compared_VBN with_IN 41_CD ._. 3_LS ±_NN 14_CD ._. 7_CD %_NN for_IN 10_CD X_NNP
          concentrated_VBD supernatant_NN (_( 
          P_NN <_NN 0_CD ._. 01_CD ,_, compared_VBN with_IN
          unconcentrated_JJ supernatant_NN )_) ,_, and_CC 47_CD ._. 3_LS ±_NN 14_CD ._. 8_CD %_NN for_IN 100_CD X_NNP
          concentrated_VBD supernatant_NN (_( 
          P_NN <_NN 0_CD ._. 01_CD ,_, compared_VBN with_IN
          unconcentrated_JJ supernatant_NN )_) ._.
          To_TO provide_VB confirmation_NN that_WDT improved_VBD transduction_NN of_IN
          FLS_NNP was_VBD associated_VBN with_IN an_DT increase_NN in_IN the_DT intracellular_NN
          expression_NN of_IN a_DT virally_RB encoded_JJ transgene_NN ,_, FLS_NNP were_VBD
          transduced_JJ with_IN a_DT vector_NN encoding_VBG human_JJ COX-_NNP 2_CD
          (_( pRET_NN 2_CD ._. COX_NNP 2_LS )_) ._. The_DT expression_NN of_IN COX-_NNP 2_CD was_VBD measured_VBN by_IN
          western_JJ blot_NN on_IN whole_JJ cell_NN lysates_NNS [_NN 6_CD ]_NN ._. A_DT substantial_JJ
          increase_NN in_IN net_JJ COX-_NNP 2_CD expression_NN was_VBD observed_VBN following_VBG
          transduction_NN with_IN both_DT 10_CD X_NNP and_CC 100_CD X_NNP concentrated_VBD viral_JJ
          supernatant_NN (_( Fig_NNP ._. 3_LS )_) ._.
        
      
      
        Discussion_NNP
        We_PRP are_VBP characterizing_VBG molecular_JJ pathways_NNS involved_VBN in_IN
        synovial_NN pathophysiology_NN by_IN overexpression_NN of_IN biologically_RB
        relevant_JJ transgenes_NNS and_CC dominant_JJ negative_JJ inhibitors_NNS in_IN
        FLS_NNP ._. The_DT limited_JJ expansion_NN potential_NN of_IN FLS_NNP ,_, combined_VBN with_IN
        the_DT low_JJ efficiency_NN of_IN existing_VBG methods_NNS ,_, stimulated_VBN a_DT
        systematic_JJ examination_NN of_IN various_JJ transduction_NN techniques_NNS
        to_TO identify_VB a_DT rapid_JJ and_CC efficient_JJ method_NN for_IN stable_JJ genetic_JJ
        modification_NN of_IN FLS_NNP ._. In_IN this_DT manuscript_NN ,_, we_PRP report_VBP a_DT
        retroviral_NN vector_NN system_NN and_CC transduction_NN protocol_NN with_IN the_DT
        capacity_NN to_TO express_VB a_DT viral_JJ transgene_NN in_IN 50_CD %_NN or_CC more_JJR of_IN
        primary_JJ human_JJ FLS_NNP after_IN a_DT single_JJ exposure_NN to_TO virus_NN ._. We_PRP have_VBP
        subsequently_RB used_VBN this_DT methodology_NN to_TO successfully_RB express_VB
        a_DT panel_NN of_IN transgenes_NNS in_IN FLS_NNP (_( L_NNP Crofford_NNP and_CC K_NNP McDonagh_NNP ,_,
        unpublished_JJ observations_NNS )_) ._. We_PRP believe_VBP this_DT approach_NN will_MD be_VB
        of_IN value_NN to_TO investigators_NNS addressing_VBG similar_JJ mechanistic_JJ
        questions_NNS in_IN FLS_NNP ._.
        Previous_JJ studies_NNS exploring_VBG the_DT use_NN of_IN recombinant_JJ MoMLV_NNP
        vectors_NNS concluded_VBD that_IN FLS_NNP were_VBD relatively_RB resistant_JJ to_TO
        transduction_NN [_NN 2_CD 3_CD 4_CD 5_CD ]_NN ,_, limiting_VBG enthusiasm_NN for_IN this_DT
        approach_NN ._. The_DT basis_NN for_IN this_DT resistance_NN was_VBD unclear_JJ ,_, but_CC
        could_MD be_VB attributable_JJ to_TO many_JJ factors_NNS including_VBG vector_NN
        design_NN ,_, viral_JJ titer_NN ,_, or_CC biologic_JJ features_NNS inherent_JJ to_TO FLS_NNP ._.
        Our_PRP$ experiments_NNS differ_VBP from_IN prior_JJ studies_NNS of_IN retroviral_NN
        gene_NN transfer_NN to_TO FLS_NNP in_IN several_JJ important_JJ respects_NNS that_WDT may_MD
        impact_VB on_IN the_DT observed_VBN results_NNS ._. First_LS ,_, our_PRP$ viral_JJ backbone_NN
        is_VBZ a_DT modified_VBN MoMLV_NNP vector_NN that_WDT incorporates_VBZ genetic_JJ
        elements_NNS (_( myeloproliferative_JJ sarcoma_NN virus_NN long-terminal_JJ
        repeats_VBZ and_CC B_NNP 2_CD mutation_NN )_) associated_VBN with_IN resistance_NN to_TO
        transcriptional_NN silencing_VBG following_VBG proviral_NN integration_NN in_IN
        primary_JJ cells_NNS [_NN 7_CD 8_CD ]_NN ._. While_IN we_PRP did_VBD not_RB perform_VB a_DT detailed_VBN
        comparison_NN of_IN EGFP_NNP expression_NN in_IN FLS_NNP using_VBG the_DT modified_VBN and_CC
        unmodified_JJ vector_NN backbones_NNS ,_, preliminary_JJ experiments_NNS
        suggested_VBD that_IN the_DT modified_VBN vector_NN was_VBD superior_JJ (_( J_NNP Yang_NNP ,_,
        unpublished_JJ observations_NNS )_) ._. A_DT similar_JJ ,_, modified_VBN MoMLV_NNP vector_NN
        has_VBZ been_VBN used_VBN to_TO stably_RB express_VB EGFP_NNP in_IN human_JJ marrow_NN
        stromal_NN cells_NNS [_NN 15_CD ]_NN ,_, another_DT fibroblast-like_JJ primary_JJ cell_NN
        type_NN ._. A_DT second_JJ distinction_NN is_VBZ the_DT use_NN of_IN EGFP_NNP as_IN a_DT
        transgene_NN ,_, whereas_IN prior_JJ studies_VBZ relied_VBN on_IN lacZ_NN or_CC
        beta-galactosidase_JJ ._. The_DT expression_NN of_IN EGFP_NNP is_VBZ readily_RB
        detectable_JJ in_IN living_VBG cells_NNS by_IN fluorescence_NN microscopy_NN or_CC
        flow_NN cytometry_NN ,_, and_CC expression_NN can_MD be_VB monitored_VBN serially_RB
        over_IN time_NN in_IN a_DT single_JJ culture_NN ._. In_IN contrast_NN to_TO staining_VBG for_IN
        lacZ_NN ,_, which_WDT is_VBZ often_RB complicated_VBN by_IN background_NN staining_VBG
        from_IN endogenous_JJ galactosidase_NN activity_NN ,_, there_EX is_VBZ no_DT
        significant_JJ background_NN staining_VBG with_IN EGFP_NNP ._. We_PRP do_VBP not_RB know_VB
        if_IN analysis_NN of_IN EGFP_NNP expression_NN is_VBZ more_JJR or_CC less_RBR sensitive_JJ
        than_IN analysis_NN for_IN lacZ_NN expression_NN ,_, although_IN we_PRP believe_VBP it_PRP
        provides_VBZ more_RBR reproducible_JJ and_CC quantitative_JJ data_NNS due_JJ to_TO the_DT
        absence_NN of_IN background_NN staining_VBG ._.
        Using_VBG this_DT vector_NN system_NN ,_, we_PRP observed_VBD a_DT low_JJ 
        ex_FW vivo_NN transduction_NN efficiency_NN (_( 14_CD ._. 2_LS
        ±_NN 8_CD ._. 2_CD %_NN )_) of_IN FLS_NNP with_IN unconcentrated_JJ supernatant_NN (_( titer_NN of_IN 10_CD
        6_CD cfu_NN /_NN ml_NN )_) that_WDT was_VBD roughly_RB comparable_JJ to_TO prior_RB reports_VBZ ._.
        Centrifugal_NNP concentration_NN of_IN viral_JJ supernatant_NN by_IN 10_CD -_: to_TO
        100_CD -_: fold_VB significantly_RB increased_VBD the_DT efficiency_NN of_IN viral_JJ
        transduction_NN ,_, with_IN 50_CD %_NN or_CC more_JJR of_IN FLS_NNP expressing_VBG EGFP_NNP in_IN
        several_JJ independent_JJ experiments_NNS using_VBG FLS_NNP lines_NNS from_IN
        separate_JJ donors_NNS ._. Concentration_NNP of_IN supernatant_NN to_TO viral_JJ
        titers_NNS exceeding_VBG 10_CD 7_CD cfu_NN /_NN ml_NN appeared_VBD to_TO have_VB the_DT greatest_JJS
        quantitative_JJ impact_NN on_IN improving_VBG transduction_NN efficiency_NN ._.
        Increasing_VBG viral_JJ titer_NN to_TO 10_CD 8_CD cfu_NN /_NN ml_NN yielded_VBD an_DT additional_JJ
        increase_NN in_IN transduction_NN efficiency_NN in_IN some_DT ,_, but_CC not_RB all_DT
        experiments_NNS ._. This_DT observation_NN suggests_VBZ that_IN factors_NNS in_IN
        addition_NN to_TO viral_JJ titer_NN may_MD limit_VB the_DT maximum_NN number_NN of_IN
        transduced_JJ FLS_NNP observed_VBD using_VBG these_DT culture_NN conditions_NNS ._.
        Lentiviral_NNP vectors_NNS have_VBP the_DT capacity_NN to_TO transduce_NN
        nonreplicating_VBG cells_NNS [_NN 16_CD ]_NN ,_, and_CC may_MD represent_VB an_DT
        alternative_NN to_TO MoMLV-based_NNP vectors_NNS for_IN some_DT
        applications_NNS ._.
      
      
        Conclusion_NNP
        We_PRP report_VBP a_DT retroviral_NN vector_NN system_NN and_CC transduction_NN
        methodology_NN that_WDT achieve_VBP stable_JJ transgene_NN expression_NN in_IN
        primary_JJ human_JJ FLS_NNP with_IN efficiencies_NNS of_IN approximately_RB 50_CD %_NN ._.
        These_DT results_NNS establish_VB the_DT feasibility_NN of_IN using_VBG widely_RB
        available_JJ retroviral_NN gene_NN transfer_NN techniques_NNS to_TO study_VB the_DT
        biologic_JJ impact_NN of_IN overexpression_NN of_IN specific_JJ regulatory_JJ
        and_CC inflammatory_JJ molecules_NNS in_IN primary_JJ FLS_NNP ._.
      
      
        Supplementary_NNP material_NN
        
          Supplementary_NNP Introduction_NNP
          Synovial_NNP cells_NNS play_VBP a_DT central_JJ role_NN in_IN the_DT
          pathophysiology_NN of_IN inflammatory_JJ arthritis_NN ._. Much_JJ of_IN our_PRP$
          understanding_NN of_IN this_DT biology_NN has_VBZ been_VBN derived_VBN from_IN the_DT
          study_NN of_IN primary_JJ fibroblast_NN like_IN synovial_NN cells_NNS cultured_JJ
          from_IN arthritic_JJ joints_NNS after_IN arthroscopic_JJ biopsy_NN or_CC
          surgery_NN ._. Stable_NNP genetic_JJ modification_NN of_IN primary_JJ synovial_NN
          cells_NNS is_VBZ an_DT approach_NN that_WDT may_MD be_VB useful_JJ in_IN defining_VBG the_DT
          roles_NNS that_IN specific_JJ signaling_VBG pathways_NNS or_CC inflammatory_JJ
          mediators_NNS play_VBP in_IN the_DT joint_JJ destruction_NN associated_VBN with_IN
          rheumatoid_NN arthritis_NN ._. As_IN our_PRP$ understanding_NN of_IN this_DT
          biology_NN improves_VBZ ,_, investigators_NNS have_VBP also_RB proposed_VBN that_DT
          gene_NN transfer_NN to_TO primary_JJ synovial_NN cells_NNS could_MD be_VB
          developed_VBN as_IN a_DT therapeutic_JJ approach_NN to_TO the_DT treatment_NN of_IN
          patients_NNS with_IN inflammatory_JJ arthritis_NN [_NN 2_CD 3_CD ]_NN ._.
          Recombinant_NNP retroviral_NN vectors_NNS are_VBP widely_RB used_VBN in_IN the_DT
          laboratory_NN ,_, and_CC in_IN experimental_JJ clinical_JJ applications_NNS ,_, to_TO
          introduce_VB new_JJ genetic_JJ material_NN into_IN the_DT host_NN genome_NN in_IN a_DT
          stable_JJ form_NN ._. Retroviral_NNP packaging_NN cells_NNS routinely_RB yield_VBP
          viral_JJ supernatants_NNS with_IN titers_NNS in_IN the_DT range_NN of_IN 10_CD 5_CD to_TO 10_CD
          6_CD cfu_NN /_NN ml_NN or_CC higher_JJR ,_, and_CC titers_NNS of_IN up_IN to_TO 10_CD 7_CD cfu_NN /_NN ml_NN may_MD be_VB
          achieved_VBN in_IN some_DT cases_NNS ._. Physical_JJ methods_NNS to_TO concentrate_VB
          viral_JJ supernatants_NNS have_VBP been_VBN pursued_VBN with_IN mixed_JJ results_NNS ._.
          Ultracentrifugation_NNP can_MD be_VB used_VBN to_TO physically_RB concentrate_VB
          MoMLV-based_NNP retroviral_NN particles_NNS ,_, but_CC viral_JJ infectivity_NN
          is_VBZ impaired_VBN secondary_JJ to_TO damage_VB to_TO the_DT envelope_NN protein_NN ._.
          Pseudotyped_NNP retroviruses_NNS containing_VBG the_DT vesicular_NN
          stomatitis_NNS virus_NN G_NNP protein_NN are_VBP more_RBR robust_JJ ,_, and_CC can_MD be_VB
          concentrated_VBN more_JJR than_IN 100_CD -_: fold_VB by_IN ultracentrifugation_NN
          without_IN significant_JJ loss_NN of_IN viral_JJ infectivity_NN ._. However_RB ,_,
          because_IN of_IN the_DT toxicity_NN of_IN the_DT vesicular_NN stomatitis_NNS virus_NN
          G_NNP glycoprotein_NN ,_, only_RB transient_JJ methods_NNS of_IN virus_NN
          production_NN have_VBP been_VBN described_VBN [_NN S_NNP 1_CD S_NNP 2_CD ]_NN ._. Bowles_NNP 
          et_CC al_NN ._. previously_RB reported_VBD a_DT
          superspeed_JJ centrifugation_NN technique_NN for_IN concentration_NN of_IN
          recombinant_JJ retrovirus_JJ [_NN 9_CD ]_NN ._. A_DT MoMLV_NNP based_VBD recombinant_JJ
          retrovirus_JJ was_VBD concentrated_VBN over_IN 100_CD -_: fold_VB by_IN
          centrifugation_NN at_IN 6000_CD 
          g_SYM for_IN 16_CD hours_NNS ._.
        
      
      
        Supplementary_NNP Materials_NNPS and_CC methods_NNS
        
          Cell_NNP culture_NN
          The_DT murine_NN fibroblast_NN NIH_NNP 3_CD T_NN 3_CD cell_NN line_NN (_( CCL_NNP 92_CD )_) and_CC
          the_DT amphotropic_JJ retroviral_NN packaging_NN cell_NN line_NN PA_NNP 317_CD (_( CRL_NNP
          9078_CD )_) were_VBD obtained_VBN from_IN the_DT American_NNP Type_NNP Culture_NNP
          Collection_NNP (_( Rockville_NNP ,_, MD_NNP ,_, USA_NNP )_) ._. The_DT Phoenix_NNP E_NNP ecotropic_JJ
          packaging_NN cell_NN line_NN was_VBD obtained_VBN from_IN Dr_NNP Gary_NNP Nolan_NNP
          (_( Stanford_NNP University_NNP ,_, USA_NNP )_) ._.
        
        
          Isolation_NNP of_IN amphotropic_JJ producer_NN cells_NNS
          A_DT transinfection_NN technique_NN was_VBD used_VBN to_TO rapidly_RB
          establish_VB a_DT polyclonal_NN amphotropic_JJ producer_NN line_NN of_IN
          moderate_JJ to_TO high_JJ titer_NN ._. The_DT pRET_NN 2_CD ._. EGFP_NNP or_CC pRET_NN 2_CD ._. COX_NNP 2_CD
          plasmids_NNS were_VBD transfected_JJ into_IN ecotropic_JJ Phoenix_NNP E_NNP
          packaging_NN cells_NNS by_IN the_DT calcium_NN phosphate_NN precipitation_NN
          method_NN ,_, using_VBG the_DT ProFection_NNP kit_NN (_( Promega_NNP ,_, Madison_NNP ,_, WI_NNP ,_,
          USA_NNP )_) ._. Retroviral_NNP supernatant_NN was_VBD collected_VBN 48_CD hours_NNS after_IN
          transfection_NN ,_, filtered_VBN through_IN a_DT 0_CD ._. 45_CD μM_NN filter_NN (_( Nalgene_NNP ,_,
          Rochester_NNP ,_, NY_NNP ,_, USA_NNP )_) ,_, supplemented_JJ with_IN 5_CD μg_NN /_NN ml_NN protamine_NN
          sulfate_NN (_( Elkins-_NNP Sinn_NNP ,_, Inc_NNP ._. Cherry_NNP Hill_NNP ,_, NJ_NNP ,_, USA_NNP )_) ,_, and_CC
          incubated_JJ with_IN amphotropic_JJ PA_NNP 317_CD packaging_NN cells_NNS for_IN 24_CD
          hours_NNS ._. The_DT transinfection_NN procedure_NN was_VBD repeated_VBN twice_RB ._.
          Following_VBG transinfection_NN with_IN ecotropic_JJ viral_JJ
          supernatant_NN ,_, 100_CD %_NN of_IN the_DT PA_NNP 317_CD cells_NNS were_VBD transduced_JJ with_IN
          the_DT pRET_NN 2_CD ._. EGFP_NNP vector_NN ,_, as_IN determined_VBN by_IN fluorescence_NN
          microscopy_NN ._. The_DT successful_JJ transinfection_NN of_IN pRET_NN 2_CD ._. COX_NNP 2_CD
          into_IN PA_NNP 317_CD was_VBD confirmed_VBN by_IN G_NNP 418_CD selection_NN ._. These_DT
          polyclonal_NN populations_NNS of_IN PA_NNP 317_CD producer_NN cells_NNS were_VBD used_VBN
          as_IN the_DT source_NN of_IN viral_JJ supernatant_NN for_IN subsequent_JJ viral_JJ
          transduction_NN and_CC concentration_NN experiments_NNS ._. The_DT presence_NN
          of_IN replication_NN competent_JJ retrovirus_JJ was_VBD excluded_VBN by_IN PCR_NNP
          for_IN viral_JJ envelope_NN coding_VBG sequence_NN in_IN genomic_JJ DNA_NNP
          isolated_VBD from_IN virally_RB transduced_JJ NIH_NNP 3_CD T_NN 3_CD target_NN cells_NNS
          (_( primers_NNS :_: 5_CD '_POS -_: AAG-GTGGTAAACCAGGGGGATC-_NNP 3_CD '_POS and_CC
          5_CD '_POS -_: TGAGCAGCT-TCATGCCGCTATC-_NNP 3_CD '_POS )_) ._.
        
        
          Quantitation_NNP of_IN viral_JJ RNA_NNP by_IN slot_NN blot_NN
          hybridization_NN
          A_DT nylon_NN transfer_NN membrane_NN (_( Micron_NNP Separations_NNP Inc_NNP ._.
          Westborough_NNP ,_, MA_NNP ,_, USA_NNP )_) was_VBD soaked_JJ in_IN 10_CD X_NNP SSC_NNP for_IN 10_CD min_NN
          and_CC inserted_VBN into_IN a_DT BRL_NNP convertible_JJ filtration_NN manifold_NN
          system_NN (_( BRL_NNP Life_NNP Technologies_NNPS Inc_NNP ._. Gaithersburg_NNP ,_, MD_NNP ,_,
          USA_NNP )_) ._. Each_DT well_RB was_VBD washed_VBN twice_RB with_IN 200_CD μl_NN of_IN 10_CD X_NNP SSC_NNP
          immediately_RB before_IN sample_NN loading_NN ._. Retroviral_NNP supernatant_NN
          samples_NNS were_VBD directly_RB loaded_VBN onto_IN the_DT membrane_NN without_IN
          further_JJ preparation_NN ._. After_IN application_NN of_IN the_DT sample_NN to_TO
          the_DT membrane_NN ,_, the_DT wells_NNS were_VBD washed_VBN three_CD times_NNS with_IN 200_CD
          μl_NN of_IN 10_CD X_NNP SSC_NNP ._. The_DT membrane_NN was_VBD cross-linked_JJ with_IN UV_NNP
          light_JJ (_( Stratalinker_NNP 1800_CD ,_, Stratagene_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP ,_, USA_NNP )_)
          and_CC stored_VBD for_IN analysis_NN by_IN hybridization_NN ._. An_DT EGFP_NNP probe_NN
          fragment_NN (_( ~_NN 800_CD base_NN pairs_NNS )_) was_VBD prepared_VBN by_IN PCR_NNP and_CC
          labeled_VBN with_IN 32_CD P-_NNP dCTP_NN (_( Amersham_NNP Life_NNP Science_NNP Inc_NNP ._. ,_,
          Arlington_NNP Heights_NNP ,_, IL_NNP ,_, USA_NNP )_) using_VBG a_DT kit_NN (_( Prime-_NNP It_PRP RmT_NNP ,_,
          Stratagene_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. The_DT membrane_NN was_VBD
          prehybridized_JJ for_IN 2_CD hours_NNS at_IN 42_CD °_NN C_NNP in_IN 10_CD ml_NN of_IN
          hybridization_NN buffer_NN (_( final_JJ concentrations_NNS :_: 50_CD %_NN
          formamide_NN ,_, 5_CD X_NNP Denhardt_NNP 's_POS solution_NN ,_, 0_CD ._. 1_CD %_NN SDS_NNP ,_, 5_CD X_NNP SSPE_NNP ,_, 150_CD
          μg_NN /_NN ml_NN denatured_JJ herring_NN sperm_NN DNA_NNP )_) ,_, and_CC hybridized_JJ with_IN
          the_DT denatured_JJ probe_NN overnight_JJ in_IN 5_CD ml_NN of_IN hybridization_NN
          buffer_NN at_IN 42_CD °_NN C_NNP ._. The_DT membrane_NN was_VBD washed_VBN twice_RB with_IN 2_CD X_NNP
          SSPE_NNP at_IN room_NN temperature_NN for_IN 10_CD min_NN ,_, three_CD times_NNS with_IN
          0_CD ._. 1_CD X_NNP SSPE_NNP /_NN 0_CD ._. 5_LS %_NN SDS_NNP at_IN 55_CD °_NN C_NNP for_IN 30_CD min_NN ,_, and_CC twice_RB with_IN
          0_CD ._. 1_CD X_NNP SSPE_NNP at_IN room_NN temperature_NN for_IN 10_CD min_NN ._. The_DT
          autoradiograph_NN was_VBD visualized_JJ by_IN exposing_VBG the_DT membrane_NN to_TO
          X-_NNP ray_NN film_NN at_IN -_: 80_CD °_NN C_NNP with_IN an_DT intensifying_VBG screen_NN ._.
        
        
          Quantitation_NNP of_IN retroviral_NN titer_NN by_IN FACS_NNP based_VBD
          expression_NN analysis_NN for_IN EGFP_NNP
          The_DT NIH_NNP 3_CD T_NN 3_CD cells_NNS were_VBD plated_JJ in_IN 6_CD -_: well_RB tissue_NN culture_NN
          dishes_NNS at_IN a_DT density_NN of_IN 10_CD 5_CD cells_NNS per_IN well_RB ._. The_DT following_VBG
          day_NN ,_, the_DT medium_NN was_VBD replaced_VBN with_IN 2_CD ml_NN of_IN fresh_JJ medium_NN
          containing_VBG a_DT defined_VBN volume_NN of_IN viral_JJ supernatant_NN ,_,
          supplemented_JJ with_IN protamine_NN sulfate_NN (_( 5_CD μg_NN /_NN ml_NN )_) ._. After_IN
          exposure_NN to_TO viral_JJ supernatant_NN for_IN 24_CD hours_NNS ,_, the_DT medium_NN
          was_VBD replaced_VBN with_IN fresh_JJ ,_, virus-free_JJ medium_NN and_CC the_DT cells_NNS
          were_VBD cultured_JJ for_IN an_DT additional_JJ 48_CD hours_NNS ._. At_IN the_DT
          conclusion_NN of_IN the_DT experiment_NN ,_, the_DT cells_NNS were_VBD trypsinized_JJ
          and_CC analyzed_VBN by_IN flow_NN cytometry_NN on_IN an_DT EPICS_NNP XL_NNP (_( excited_VBN by_IN
          488_CD nm_NN light_JJ ,_, using_VBG a_DT 530_CD ±_NN 15_CD nm_NN bandpass_NNS filter_NN to_TO
          detect_VB the_DT signal_NN on_IN FL_NNP 1_LS )_) to_TO determine_VB the_DT percentage_NN of_IN
          cells_NNS expressing_VBG EGFP_NNP ._. In_IN all_DT cases_NNS ,_, serial_NN dilutions_NNS of_IN
          viral_JJ supernatant_NN were_VBD tested_VBN ._.
        
      
      
        Supplementary_NNP Results_NNS
        
          Optimization_NNP of_IN the_DT centrifugation_NN protocol_NN
          
            Duration_NNP of_IN centrifugation_NN
            Supernatant_NNP collected_VBD from_IN the_DT RET_NNP 2_CD ._. EGFP_NNP producer_NN
            cells_NNS was_VBD centrifuged_JJ at_IN 6000_CD 
            g_SYM for_IN time_NN periods_NNS varying_VBG
            between_IN 1_CD and_CC 20_CD hours_NNS ._. After_IN centrifugation_NN ,_, the_DT
            supernatant_NN was_VBD collected_VBN and_CC saved_VBN for_IN quantitation_NN of_IN
            residual_JJ viral_JJ particles_NNS ._. The_DT viral_JJ pellets_NNS were_VBD
            resuspended_JJ in_IN a_DT thirtieth_NN of_IN the_DT original_JJ volume_NN of_IN
            the_DT supernatant_NN ._. As_IN measured_VBN on_IN NIH_NNP 3_CD T_NN 3_CD cells_NNS by_IN flow_NN
            cytometry_NN ,_, viral_JJ titer_NN increased_VBD 14_CD -_: fold_VB after_IN four_CD
            hours_NNS of_IN centrifugation_NN ,_, and_CC appeared_VBD to_TO plateau_NN after_IN
            12_CD hours_NNS of_IN centrifugation_NN at_IN 1_CD ._. 34_CD ×_NN 10_CD 7_CD cfu_NN /_NN ml_NN
            (_( Supplementary_NNP Fig_NNP ._. 1_LS )_) ._. There_EX was_VBD a_DT proportional_JJ
            decline_NN in_IN the_DT viral_JJ titer_NN of_IN the_DT postcentrifugation_NN
            supernatant_NN ._. Even_RB following_VBG concentration_NN for_IN as_RB long_RB
            as_IN 20_CD hours_NNS ,_, the_DT infectivity_NN of_IN the_DT recombinant_JJ virus_NN
            was_VBD preserved_VBN ._.
            To_TO confirm_VB the_DT viral_JJ titer_NN derived_VBN by_IN expression_NN
            analysis_NN ,_, we_PRP performed_VBD slot_NN blot_NN hybridization_NN analysis_NN
            on_IN viral_JJ RNA_NNP in_IN the_DT postcentrifugation_NN supernatant_NN and_CC
            the_DT resuspended_JJ viral_JJ pellet_NN (_( Supplementary_NNP Fig_NNP ._. 2_LS )_) ._.
            Following_VBG centrifugation_NN at_IN 6000_CD 
            g_SYM for_IN four_CD hours_NNS ,_, most_JJS retroviral_NN
            RNA_NNP was_VBD concentrated_VBN in_IN the_DT viral_JJ pellet_NN ._. Almost_RB no_DT
            retroviral_NN RNA_NNP remained_VBD in_IN the_DT postcentrifugation_NN
            supernatant_NN after_IN centrifugation_NN for_IN 12_CD hours_NNS ._.
          
          
            Relative_NNP centrifugal_JJ force_NN
            To_TO further_VB optimize_NN the_DT concentration_NN procedure_NN ,_, we_PRP
            examined_VBD a_DT range_NN of_IN relative_JJ centrifugal_JJ force_NN (_( RCF_NNP )_) ._.
            The_DT time_NN of_IN centrifugation_NN was_VBD fixed_VBN at_IN four_CD hours_NNS and_CC
            the_DT RCF_NNP was_VBD varied_VBN in_IN a_DT range_NN from_IN 6000_CD to_TO 30_CD ,_, 000_CD 
            g_SYM ._. Following_VBG centrifugation_NN ,_, the_DT
            viral_JJ pellet_NN was_VBD resuspended_JJ in_IN a_DT hundredth_JJ of_IN the_DT
            original_JJ volume_NN ._. Viral_NNP titer_NN was_VBD quantitated_JJ by_IN
            expression_NN studies_NNS in_IN NIH_NNP 3_CD T_NN 3_CD cells_NNS (_( Supplementary_NNP Fig_NNP ._.
            3_LS )_) and_CC slot_NN blot_NN hybridization_NN analysis_NN (_( Supplementary_NNP
            Fig_NNP ._. 4_LS )_) ._. We_PRP observed_VBD a_DT progressive_JJ rise_NN in_IN viral_JJ titer_NN
            as_IN RCF_NNP was_VBD increased_VBN from_IN 6000_CD to_TO 20_CD ,_, 000_CD 
            g_SYM ._. At_IN a_DT RCF_NNP of_IN 20_CD ,_, 000_CD 
            g_SYM ,_, the_DT titer_NN of_IN the_DT resuspended_JJ
            pellet_NN reached_VBD a_DT plateau_NN value_NN of_IN 1_CD ._. 3_CD ×_NN 10_CD 8_CD cfu_NN /_NN ml_NN ._.
            Further_RB concentration_NN of_IN viral_JJ particles_NNS was_VBD not_RB
            achieved_VBN by_IN increasing_VBG RCF_NNP above_IN 20_CD ,_, 000_CD 
            g_SYM ._. Viral_NNP particles_NNS were_VBD not_RB
            detectable_JJ by_IN expression_NN assay_NN or_CC by_IN slot_NN blot_NN
            hybridization_NN analysis_NN in_IN the_DT post-centrifugation_JJ
            supernatant_NN at_IN an_DT RCF_NNP of_IN 20_CD ,_, 000_CD 
            g_SYM or_CC higher_JJR ._. The_DT expression_NN data_NN
            also_RB suggested_VBD that_DT centrifugation_NN at_IN a_DT RCF_NNP as_RB high_JJ as_IN
            30_CD ,_, 000_CD 
            g_SYM for_IN four_CD hours_NNS did_VBD not_RB affect_VB
            viability_NN of_IN the_DT recombinant_JJ retrovirus_JJ ._.
          
        
      
      
        Supplementary_NNP Discussion_NNP
        The_DT FLS_NNP are_VBP the_DT principal_JJ cell_NN type_NN of_IN sublining_VBG
        synovial_NN tissue_NN ._. Proliferation_NNP of_IN FLS_NNP is_VBZ observed_VBN in_IN RA_NNP ,_, a_DT
        debilitating_JJ condition_NN that_WDT affects_VBZ as_RB many_JJ as_IN 1_CD -_: 2_CD %_NN of_IN
        adult_NN individuals_NNS worldwide_NN ._. Primary_JJ FLS_NNP cultures_NNS can_MD be_VB
        established_VBN following_VBG arthroscopic_JJ biopsy_NN or_CC surgical_JJ
        resection_NN of_IN synovium_NN from_IN the_DT joint_NN ._. Protease_NNP digested_VBN
        synovial_NN tissues_NNS placed_VBN in_IN culture_NN rapidly_RB yield_VB
        fibroblast-like_JJ cells_NNS ._. After_IN three_CD passages_NNS ,_, these_DT primary_JJ
        cultures_NNS are_VBP depleted_VBN of_IN macrophage-like_JJ type_NN A_DT
        synoviocytes_NNS [_NN S_NNP 3_CD ]_NN ._. Doubling_NNP time_NN is_VBZ stable_JJ between_IN the_DT
        third_JJ and_CC the_DT tenth_NN passages_NNS ,_, but_CC marked_VBD reduction_NN in_IN
        proliferation_NN rate_NN occurs_VBZ in_IN later_RB passage_NN cells_NNS [_NN S_NNP 4_CD ]_NN
        ._.
        Retroviral_NNP mediated_JJ gene_NN transfer_NN is_VBZ a_DT commonly_RB used_VBN
        technique_NN to_TO stably_RB introduce_VB genes_NNS into_IN primary_JJ cells_NNS ._. The_DT
        titer_NN of_IN retroviral_NN supernatant_NN is_VBZ one_CD of_IN several_JJ factors_NNS
        that_WDT influence_NN transduction_NN efficiency_NN ._. A_DT variety_NN of_IN
        strategies_NNS have_VBP been_VBN employed_VBN to_TO physically_RB concentrate_VB
        retroviral_NN particles_NNS in_IN an_DT attempt_NN to_TO further_VB increase_NN
        viral_JJ titer_NN and_CC improve_VB the_DT efficiency_NN of_IN target_NN cell_NN
        transduction_NN ._. Centrifugation_NNP of_IN retroviral_NN supernatant_NN is_VBZ a_DT
        potentially_RB attractive_JJ approach_NN to_TO viral_JJ concentration_NN
        because_IN of_IN the_DT wide_JJ availability_NN of_IN centrifuge_NN equipment_NN ,_,
        the_DT simplicity_NN of_IN the_DT technique_NN ,_, and_CC the_DT theoretical_JJ
        potential_NN for_IN rapid_JJ processing_NN of_IN large_JJ sample_NN volumes_NNS ._.
        Concentrated_NNP recombinant_JJ retrovirus_JJ ,_, generated_VBN by_IN
        super-speed_JJ centrifugation_NN of_IN retroviral_NN supernatant_NN ,_, has_VBZ
        been_VBN used_VBN to_TO improve_VB the_DT transduction_NN efficiency_NN of_IN primary_JJ
        cells_NNS ,_, including_VBG hepatocytes_NNS [_NN 9_CD ]_NN and_CC endothelial_NN cells_NNS [_NN
        11_CD ]_NN ._. In_IN these_DT prior_JJ reports_VBZ ,_, concentration_NN was_VBD
        accomplished_VBN by_IN centrifugation_NN for_IN 16_CD hours_NNS at_IN a_DT RCF_NNP of_IN
        6000_CD 
        g_SYM ._. We_PRP used_VBD a_DT recombinant_JJ retrovirus_JJ
        encoding_VBG the_DT green_JJ fluorescent_NN protein_NN to_TO optimize_NN a_DT
        protocol_NN to_TO rapidly_RB and_CC efficiently_RB concentrate_VB retrovirus_JJ
        by_IN superspeed_JJ centrifugation_NN ._. Our_PRP$ studies_NNS indicate_VBP that_IN the_DT
        time_NN necessary_JJ to_TO recover_VB essentially_RB all_DT viral_JJ particles_NNS
        can_MD be_VB reduced_VBN to_TO four_CD hours_NNS by_IN increasing_VBG the_DT RCF_NNP to_TO
        20_CD ,_, 000_CD 
        g_SYM ._. The_DT protocol_NN does_VBZ not_RB appear_VB to_TO
        adversely_RB affect_VB the_DT infectivity_NN of_IN the_DT viral_JJ preparation_NN ,_,
        as_IN the_DT functional_JJ viral_JJ titer_NN on_IN NIH_NNP 3_CD T_NN 3_CD cells_NNS closely_RB
        matched_VBD the_DT titer_NN that_WDT was_VBD predicted_VBN by_IN the_DT degree_NN of_IN
        concentration_NN ._. Although_IN it_PRP has_VBZ been_VBN reported_VBN that_DT
        centrifugation_NN may_MD result_VB in_IN concurrent_JJ concentration_NN of_IN
        noninfectious_JJ viral_JJ particles_NNS or_CC inhibitors_NNS of_IN viral_JJ
        transduction_NN [_NN S_NNP 5_CD ]_NN ,_, we_PRP have_VBP been_VBN able_JJ to_TO substantially_RB
        increase_VB the_DT transduction_NN efficiency_NN of_IN primary_JJ FLS_NNP using_VBG
        concentrated_VBN viral_JJ supernatant_NN produced_VBN by_IN our_PRP$ protocol_NN ._.
        This_DT optimized_JJ technique_NN may_MD be_VB useful_JJ in_IN generating_NN high_JJ
        titer_NN retroviral_NN supernatants_NNS from_IN production_NN lots_NNS of_IN
        relatively_RB modest_JJ titer_NN ._. We_PRP anticipate_VBP that_IN this_DT method_NN
        will_MD be_VB effective_JJ in_IN concentrating_VBG other_JJ pseudotyped_JJ MoMLV_NNP
        vectors_NNS and_CC lentivirus_JJ based_VBN vectors_NNS ,_, though_IN additional_JJ
        testing_NN will_MD be_VB required_VBN to_TO evaluate_VB its_PRP$ suitability_NN for_IN
        each_DT vector_NN system_NN ._.
        While_IN our_PRP$ studies_NNS were_VBD not_RB initiated_VBN with_IN the_DT objective_NN
        of_IN developing_VBG a_DT therapeutic_JJ protocol_NN ,_, these_DT results_NNS may_MD
        also_RB have_VB implications_NNS for_IN clinical_JJ studies_NNS ._. The_DT 
        ex_FW vivo_NN genetic_JJ modification_NN of_IN FLS_NNP
        has_VBZ been_VBN proposed_VBN as_IN a_DT potential_JJ approach_NN to_TO the_DT treatment_NN
        of_IN arthritis_NN [_NN S_NNP 6_CD S_NNP 7_CD ]_NN ._. In_IN these_DT studies_NNS ,_, FLS_NNP are_VBP cultured_JJ
        from_IN synovial_NN tissue_NN obtained_VBN by_IN synovectomy_NN ,_, transduced_JJ
        with_IN retroviral_NN supernatant_NN 
        ex_FW vivo_NN ,_, and_CC injected_VBD into_IN another_DT
        joint_NN of_IN the_DT same_JJ individual_NN ._. Approval_NNP for_IN these_DT clinical_JJ
        studies_NNS was_VBD based_VBN on_IN 
        ex_FW vivo_NN transduction_NN data_NNS in_IN
        preclinical_JJ animal_NN models_NNS [_NN S_NNP 8_CD S_NNP 9_CD ]_NN ._. Essentially_RB ,_, all_DT data_NNS
        on_IN transduction_NN efficiency_NN of_IN FLS_NNP was_VBD derived_VBN using_VBG
        retroviral_NN vectors_NNS that_WDT express_VBP lacZ_NN or_CC beta-galactosidase_JJ ._.
        Although_IN most_JJS authors_NNS have_VBP obtained_VBN 
        ex_FW vivo_NN transduction_NN efficiencies_NNS of_IN
        cultured_JJ FLS_NNP in_IN the_DT range_NN of_IN 1_CD -_: 5_CD %_NN ,_, some_DT have_VBP reported_VBN
        transduction_NN efficiencies_NNS up_IN to_TO 20_CD %_NN ._. Preactivation_NNP of_IN FLS_NNP
        with_IN tumor_NN necrosis_NNS factor_NN α_NN ,_, however_RB ,_, may_MD increase_VB
        transduction_NN efficiency_NN levels_NNS to_TO over_IN 30_CD %_NN [_NN S_NNP 8_CD ]_NN ._.
      
      
        Abbreviations_NNP
        cfu_NN =_SYM colony_NN forming_VBG units_NNS ;_: COX-_NNP 2_CD =_SYM cyclooxygenase-_NN 2_CD ;_:
        DMEM_NNP =_SYM Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS medium_NN ;_: EGFP_NNP =_SYM enhanced_VBN
        green_JJ fluorescent_NN protein_NN ;_: FACS_NNP =_SYM fluorescence-activated_JJ
        cell_NN sorting_VBG ;_: FLS_NNP =_SYM fibroblast-like_JJ synovial_NN cells_NNS ;_: MoMLV_NNP =_SYM
        Moloney_NNP murine_NN leukemia_NN virus_NN ;_: PCR_NNP =_SYM polymerase_NN chain_NN
        reaction_NN ;_: RA_NNP =_SYM rheumatoid_NN arthritis_NN ;_: RCF_NNP =_SYM relative_JJ
        centrifugal_JJ force_NN ._.
      
    
  
